Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Victoria Hillerdal"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Adoptive T-cell therapy of cancer is a treatment strategy where T cells are isolated, activated, in some cases engineered, and expanded ex vivo before being reinfused to the patient. The most commonly used T-cell expansion methods are either anti-CD3
Externí odkaz:
https://doaj.org/article/24143455db0b40099ac9e101fa92eaab
Autor:
Kalle Söderström, Andre Simoes, Andrew Hutton, Rebecca Alade, Istvan Kovacs, Mihil Patel, Oliver Nussbaumer, Daniel W. Fowler, Joanna Kawalkowska, Victoria Hillerdal, Michael Koslowski, Tim Recaldin, Alice Brown, Elizabeth Reynolds, Katharina Bergerhoff, Valentino Parravicini
Publikováno v:
Cancer Research. 80:888-888
The treatment of haematologic malignancies with adoptive cell therapy is largely limited to platforms based on patient-derived, autologous αβ T cells. Although successful, this approach comes with challenges including associated toxicities, risk of
Autor:
Victoria Hillerdal, Magnus Essand
Publikováno v:
Biodrugs
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineere
Publikováno v:
BMC Immunology
Background: Adoptive transfer of genetically engineered autologous T-cells is becoming a successful therapy for cancer. The avidity of the engineered T-cells is of crucial importance for therapy success. We have in the past cloned a T-cell receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cafed2df07737766c79dbfd213e5c4bc
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300454
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300454
Publikováno v:
Proceedings of the National Academy of Sciences. 109:15877-15881
To produce genetically engineered T cells directed against prostate and breast cancer cells, we have cloned the T-cell receptor recognizing the HLA-A2–restricted T-cell recptor γ-chain alternate reading-frame protein (TARP) 4–13 epitope. TARP is
Publikováno v:
BMC Cancer
Background Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers. Experimental therapy with CA
Publikováno v:
Cancer Research. 73:A7-A7
In order to produce genetically engineered T cells directed against prostate and breast cancer cells we have cloned the T cell receptor recognizing the human leukocyte antigen (HLA)-A2-restricted TARP4-13 epitope. TARP is a protein exclusively expres